Effect of Metformin and Vitamin D Supplementation on Metabolic and Hormonal Profiles in Polycystic Ovary Syndrome Women: A Follow-Up Study
Zainab Nur-Eldeen Aziz 1*, Basil O. Saleh 1
Journal of Angiotherapy 8(1) 1-7 https://doi.org/10.25163/angiotherapy.819438
Submitted: 18 December 2023 Revised: 21 January 2024 Published: 22 January 2024
Abstract
Background: Insulin resistance in association with obesity is implicated in the pathogenesis of polycystic ovarian syndrome and its primary characteristic of hyperandrogenism. Metformin at a dose of (1700-2000) mg/day, with and without lifestyle, is associated with a beneficial enhancement in BMI and menstrual cycles. We aimed to determine the role of free testosterone: dihydrotestosterone ratio, and sex hormone binding globulin in the evaluation of the efficacy of metformin and vitamin D in the treatment of polycystic ovary syndrome. Methods: This cross-sectional study included 50 infertile women who were diagnosed with PCOS with an age range of (18-40 years). They were classified into Group I: Twenty-five women treated with metformin 850 mg/twice daily and followed for 8 weeks; Group II: Twenty-five women treated with vitamin D3 50.000 IU/wk for the same period. Serum investigations included measurements of prolactin, 25 hydroxyvitamin D, LH, FSH, free testosterone, DHT and SHBG by ELISA technique. Results: This study revealed that the mean values of BMI, HOMA-IR, prolactin and free testosterone: dihydrotestosterone ratio were significantly improved (by lowering) after treatment with metformin and vitamin D. Moreover, Polycystic Ovary Syndrome women treated with metformin revealed significant negative association between HOMA-IR with SHBG (r= -0.593, p=0.009), also significant positive association between HOMA-IR with BMI (r= 0.631, p=0.003). Conclusion: Serum measurements of free testosterone: dihydrotestosterone ratio, along with SHBG, are good biochemical markers that reflect the enhancement of insulin resistance and BMI in Polycystic Ovary Syndrome women post metformin treatment or vitamin D supplementation.
Keywords. Polycystic Ovary Syndrome (PCOS), prolactin, androgen hormone, HOMA-IR, metformin, vitamin D
References
Alawad, Z. M. (2018). Level of follicular fluid vitamin D and embryo quality in a sample of Iraqi women undergoing IVF. Journal of the Faculty of Medicine Baghdad, 60(4), 215–221.
Alomda, F. A. E.-A., Hashish, M. A. E.-L., El-Naggar, W. E.-S., & Mosallam, A. M. A. E.-R. (2019). The effect of vitamin D supplementation on the androgenic profile in patient with polycystic ovary syndrome. The Egyptian Journal of Hospital Medicine, 75(3), 2461–2466.
Angellotti, E., D’Alessio, D., Dawson-Hughes, B., Nelson, J., Cohen, R. M., Gastaldelli, A., & Pittas, A. G. (2018). Vitamin D supplementation in patients with type 2 diabetes: the vitamin D for established type 2 diabetes (DDM2) study. Journal of the Endocrine Society, 2(4), 310–321.
Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022). Controversies in the pathogenesis, diagnosis and treatment of PCOS: focus on insulin resistance, inflammation, and hyperandrogenism. International Journal of Molecular Sciences, 23(8), 4110.
Deswal, R., Narwal, V., Dang, A., & Pundir, C. S. (2020). The prevalence of polycystic ovary syndrome: a brief systematic review. Journal of Human Reproductive Sciences, 13(4), 261.
Gokosmanoglu, F., Onmez, A., & Ergenç, H. (2020). The relationship between Vitamin D deficiency and polycystic ovary syndrome. African Health Sciences, 20(4), 1880–1886.
Hamdi, R. A., Abdul-Qahar, Z. H., Kadhum, E. J., & Alsaeed, F. A. (2018). Assessment of Serum Vitamin D Levels in Women with Polycystic Ovary Syndrome. Journal of the Faculty of Medicine Baghdad, 60(2), 93–97.
Herman, R., Kravos, N. A., Jensterle, M., Janež, A., & Dolžan, V. (2022). Metformin and insulin resistance: A review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. International Journal of Molecular Sciences, 23(3), 1264.
Lashen, H. (2010). Role of metformin in the management of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 1(3), 117–128.
Lewandowski, K. C., Skowronska-Józwiak, E., Lukasiak, K., Galuszko, K., Dukowicz, A., Cedro, M., & Lewinski, A. (2019). How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models. Archives of Medical Science, 15(3), 613–618.
Menichini, D., & Facchinetti, F. (2019). Effects of vitamin D supplementation in women with polycystic ovary syndrome: a review. Gynecological Endocrinology.
Mohan, A., Haider, R., Fakhor, H., Hina, F., Kumar, V., Jawed, A., Majumder, K., Ayaz, A., Lal, P. M., & Tejwaney, U. (2023). Vitamin D and polycystic ovary syndrome (PCOS): A review. Annals of Medicine and Surgery, 85(7), 3506–3511.
Morgante, G., Darino, I., Spanò, A., Luisi, S., Luddi, A., Piomboni, P., Governini, L., & De Leo, V. (2022). PCOS physiopathology and vitamin D deficiency: biological insights and perspectives for treatment. Journal of Clinical Medicine, 11(15), 4509.
Organization, W. H. (2004). International Statistical Classification of Diseases and related health problems: Alphabetical index (Vol. 3). World Health Organization.
Pasquali, R. (2018). Contemporary approaches to the management of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 9(4), 123–134.
Qasim, M. N., Kadhem, H. K., & EL-Yassin, H. D. (2022). CORRELATION BETWEEN VITAMIN D3 DEFICIENCY AND SERUM LEPTIN LEVELS IN A PATIENT WITH POLYCYSTIC OVARY SYNDROME. Biochemical & Cellular Archives, 22(2).
Rotterdam, E. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 81(1), 19–25.
Saleh, B. O., Ibraheem, W. F., & Ameen, N. S. (2015). The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome. Saudi Medical Journal, 36(5), 562.
Shah, S., Banu, H., Sultana, T., Akhtar, N., Begum, A., Zamila, B. M., Fariduddin, M., & Hasanat, M. A. (2019). Increased ratio of total testosterone to dihydrotestosterone may predict an adverse metabolic outcome in polycystic ovary syndrome. Journal of Endocrinology and Metabolism, 9(6), 186–192.
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023). Polycystic ovary syndrome: etiology, current management, and future therapeutics. Journal of Clinical Medicine, 12(4), 1454.
Teede, H., Tassone, E. C., Piltonen, T., Malhotra, J., Mol, B. W., Peña, A., Witchel, S. F., Joham, A., McAllister, V., & Romualdi, D. (2019). Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clinical Endocrinology, 91(4), 479–489.
Williams, A., Babu, J. R., Wadsworth, D. D., Burnett, D., & Geetha, T. (2020). The effects of vitamin D on metabolic profiles in women with polycystic ovary syndrome: a systematic review. Hormone and Metabolic Research, 52(07), 485–491.
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019). Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society, 3(8), 1545–1573.
Xue, Y., Xu, P., Xue, K., Duan, X., Cao, J., Luan, T., Li, Q., & Gu, L. (2017). Effect of vitamin D on biochemical parameters in polycystic ovary syndrome women: a meta-analysis. Archives of Gynecology and Obstetrics, 295, 487–496.
Zhao, J.-F., Li, B.-X., & Zhang, Q. (2021). Vitamin D improves levels of hormonal, oxidative stress and inflammatory parameters in polycystic ovary syndrome: a meta-analysis study. Ann. Palliat. Med, 10(1), 169–183.
Zhuang, L., Wei, C. U. I., Jianxiang, C., & Zhang, Y. (2019). Efficacy of vitamin D combined with metformin and clomiphene in the treatment of patients with polycystic ovary syndrome combined with infertility. Iranian Journal of Public Health, 48(10), 1802.
View Dimensions
View Altmetric
Save
Citation
View
Share